Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Immunic, retaining the price target of $10.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Matthew Caufield has given his Buy rating due to a combination of factors surrounding Immunic’s lead candidate, vidofludimus calcium, and its potential in treating multiple sclerosis (MS). The drug’s unique dual mechanism, which includes neuroprotection through Nurr1 activation and relapse prevention via DHODH inhibition, positions it as a promising treatment that could address both relapsing and progressive forms of MS. This differentiation is crucial as it targets unmet needs that current standard-of-care therapies do not fully address.
Furthermore, the completion of Phase 3 enrollment for the ENSURE-1 and ENSURE-2 trials in relapsing MS, with pivotal topline data expected by the end of 2026, adds to the optimism. The positive outcomes from earlier Phase 2 trials and the potential for vidofludimus calcium to slow disease progression independent of relapse activity underscore its therapeutic promise. These factors, combined with the need for safer and better-tolerated therapies in MS, support Caufield’s Buy rating and the $10 price target.
Caufield covers the Healthcare sector, focusing on stocks such as LENZ Therapeutics, Immunic, and Opus Genetics. According to TipRanks, Caufield has an average return of 16.7% and a 49.52% success rate on recommended stocks.
In another report released on October 16, Ladenburg Thalmann & Co. also initiated coverage with a Buy rating on the stock with a $3.00 price target.